Evidence map›Paper›PMID 40375930›Full record

ArticleFrontiers in medicine2025

Bridging the gap: enhancing blood regulatory functions in African contexts through comparative analysis.

Washington T Samukange, Verena Kluempers, Chancelar Kafere, Kristina Heinrich, Joanna Atemnkeng, Alireza Khadem Broojerdi, Florence Tirane, Edwin Nkansah, Shani Maboko, Linda Nhukarume and 5 more

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Current State of in vitro Diagnostics Evaluation in Sub-Saharan African Countries: Insights from the Advanced Workshop.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Washington T SamukangeCentre for International Cooperation, Paul-Ehrlich-Institut, Langen, Germany.
Verena KluempersCentre for International Cooperation, Paul-Ehrlich-Institut, Langen, Germany.
Chancelar KafereCentre for International Cooperation, Paul-Ehrlich-Institut, Langen, Germany.
Kristina HeinrichCentre for International Cooperation, Paul-Ehrlich-Institut, Langen, Germany.
Joanna AtemnkengCentre for International Cooperation, Paul-Ehrlich-Institut, Langen, Germany.
Alireza Khadem BroojerdiWorld Health Organisation, Regulatory Systems Strengthening, Regulation and Safety Unit, Geneva, Switzerland.
Florence TiraneZambia Medicines Regulatory Authority, Lusaka, Zambia.
Edwin NkansahFood and Drugs Authority Ghana, Accra, Ghana.
Shani MabokoTanzania Medicine and Medical Devices Authority, Dodoma, Tanzania.
Linda NhukarumeMedicines Control Authority of Zimbabwe (MCAZ), Harare, Zimbabwe.
Khamusi MutotiSouth African Health Products Regulatory Authority (SAHPRA), Pretoria, South Africa.
Noel AineplanNational Drug Authority (NDA), Kampala, Uganda.
Helga GardasdottirDivision of Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands.
Aukje K Mantel-TeeuwisseDivision of Pharmacoepidemiology & Clinical Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, Netherlands.
Jens ReinhardtDivision of Haematology, Cell and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Introduction: Independent assessments of blood regulatory systems, facilitated by tools such as the WHO's Global Benchmarking Tool (GBT) plus Blood expedites development of National Regulatory Authorites (NRAs) and thus promotes increased access to safe, effective, and quality blood, blood components, and products. The aim of this study was to assess and compare the status of implementation and performance of the regulatory functions for registration and marketing authorization as well as the system for approval of blood, blood components and plasma for fractionation or processes. Methods: We did this by conducting assisted self-benchmarking in 12 African countries using the GBT plus Blood (registration and marketing authorization function, 34 sub-indicators and approval of blood, blood components, and plasma for fractionation or processes function, 24 sub-indicators). Comparative assessments of WHO-designated maturity level 3 (ML3) NRAs for medicines and vaccines against non-designated NRAs were made. Results: The percentage of implemented sub-indicators was higher for the registration and marketing authorization function with an average implementation score of 73% (range: 51%-92%) compared to the approval of blood, blood components, and plasma for fractionation or processes function which had an average implementation score of 45% (range: 6%-65%). The comparison of group averages for the ML3-designated NRAs against the non-designated NRAs revealed a higher score 91% (range: 71%-100%) for ML3-designated NRAs as opposed to a lower score of 71% (range: 49%-100%) for the non-designated NRAs for the registration and marketing authorization function. This pattern, however, was not observed for the comparison of group averages for the approval of blood, blood components, and plasma for fractionation or processes function where the ML3-designated NRAs scored 47% (range 19%-72%) against 46% (range 23%-88%) for the non-ML3-designated NRAs. Conclusion: Most of the NRAs excelled in implementing sub-indicators for the registration and marketing authorization (of plasma-derived medicines) function. All NRAs exhibited notable flaws in regulating blood, blood components, plasma for fraction, and approval of processes, indicating nascent regulatory frameworks. This study highlights the urgent need for WHO and African countries to prioritize formal benchmarking of NRAs using the GBT plus Blood to enhance their regulatory capacities in blood and blood product regulation.

Indexed as

availability of safe bloodblood and blood productsGHPP BloodTrainglobal benchmarking toolSub-Saharan African countries

Identifiers

PMID40375930
PMCPMC12078219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.